Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach
Juliana Ochoa-Grullón, Celina Benavente Cuesta, Ataúlfo González Fernández, Gustavo Cordero Torres, Cristina Pérez López, Ascensión Peña Cortijo, Laura Conejero Hall, Marta Mateo Morales, Antonia Rodríguez de la Peña, Carmen M Díez-Rivero, Edgard Rodríguez de Frías, Kissy Guevara-Hoyer, Miguel Fernández-Arquero, Silvia Sánchez-Ramón, Juliana Ochoa-Grullón, Celina Benavente Cuesta, Ataúlfo González Fernández, Gustavo Cordero Torres, Cristina Pérez López, Ascensión Peña Cortijo, Laura Conejero Hall, Marta Mateo Morales, Antonia Rodríguez de la Peña, Carmen M Díez-Rivero, Edgard Rodríguez de Frías, Kissy Guevara-Hoyer, Miguel Fernández-Arquero, Silvia Sánchez-Ramón
Abstract
Infectious complications are a major cause of morbidity and mortality in B-cell hematological malignancies (HM). Prophylaxis for recurrent infections in HM patients with antibody deficiency consists of first-line antibiotics and when unsuccessful, gammaglobulin replacement therapy (IgRT). Recent knowledge of trained immunity-based vaccines (TIbV), such as the sublingual polybacterial formulation MV130, has shown a promising strategy in the management of patients with recurrent infections. We sought to determine the clinical benefit of MV130 in a cohort of HM patients with recurrent respiratory tract infections (RRTIs) who underwent immunization with MV130 for 3 months. Clinical information included the frequency of infections, antibiotic use, number of visits to the GP and hospitalizations previous and after MV130 immunotherapy. Improvement on infection rate was classified as: clear (>60% reduction of infection), partial (26%-60%) and low (≤25%) improvement. Fifteen HM patients (aged 42 to 80 years; nine females) were included in the study. All patients reduced their infection rate. Analysis of paired data revealed that the median (range, min - max) of respiratory infectious rate significantly decreased from 4.0 (8.0-3.0) to 2.0 (4.0-0.0) (p<0.001) at 12 months of MV130. A clear clinical improvement was observed in 53% (n = 8) of patients, partial improvement in 40% (n = 6) and low improvement in 7% (n = 1). These data correlated with a decrease on antibiotic consumption from 3.0 (8.0-1.0) to 1.0 (2.0-0.0) (p = 0.002) during 12 months after initiation of treatment with MV130. The number of infectious-related GP or emergency room visits declined from 4.0 (8.0-2.0) to 2.0 (3.0-0.0) (p<0.001), in parallel with a reduction in hospital admissions due to infections (p = 0.032). Regarding safety, no adverse events were observed. On the other hand, immunological assessment of serum IgA and IgG levels demonstrated an increase in specific antibodies to MV130-contained bacteria following MV130 immunotherapy. In conclusion, MV130 may add clinical benefit reducing the rate of infections and enhancing humoral immune responses in these vulnerable patients.
Keywords: IgA; MV130; hematological malignancies; prophylaxis; recurrent respiratory tract infections; trained immunity-based vaccines.
Conflict of interest statement
LC and CD-R belong to the Immunotek R+D Department. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2021 Ochoa-Grullón, Benavente Cuesta, González Fernández, Cordero Torres, Pérez López, Peña Cortijo, Conejero Hall, Mateo Morales, Rodríguez de la Peña, Díez-Rivero, Rodríguez de Frías, Guevara-Hoyer, Fernández-Arquero and Sánchez-Ramón.
Figures
References
- Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach: When to initiate IgG therapy in antibody deficiency. Clin Exp Immunol (2017) 188:333–41. 10.1111/cei.12915
- Wingard JR, Hsu J, Hiemenz JW. Hematopoietic Stem Cell Transplantation: An Overview of Infection Risks and Epidemiology. Hematol/Oncol Clinics North America (2011) 25:101–16. 10.1016/j.hoc.2010.11.008
- Cho S-Y, Lee H-J, Lee D-G. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. Korean J Internal Med (2018) 33:256–76. 10.3904/kjim.2018.036
- Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Global Health (2015) 109:309–18. 10.1179/2047773215Y.0000000030
- Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Global Infect Dis (2019) 11:36. 10.4103/jgid.jgid_110_18
- Dinh A, Davido B, Duran C, Bouchand F, Bernard L. Antibiotic prophylaxis approaches for urinary tract infections. Lancet Infect Dis (2018) 18:1065. 10.1016/S1473-3099(18)30501-2
- Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. . Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol (2018) 36:3043–54. 10.1200/JCO.18.00374
- Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr (2016) 4:1–24. 10.1128/microbiolspec.VMBF-0016-2015
- Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. . Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist (2018) 11:1645–58. 10.2147/IDR.S173867
- O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist (2016) 2–80.
- Sanchez-Ramon S, Diego R, Dieli-Crimi R, Subiza J-L. Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects. Curr Drug Targets (2014) 15:1132–43. 10.2174/1389450115666141020160705
- Stevens WBC, Netea MG, Kater AP, van der Velden WJFM. ‘Trained immunity: consequences for lymphoid malignancies. Haematologica (2016) 101:1460–8. 10.3324/haematol.2016.149252
- Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. . Defining trained immunity and its role in health and disease. Nat Rev Immunol (2020) 20:375–88. 10.1038/s41577-020-0285-6
- Mourits VP, Wijkmans JC, Joosten LA, Netea MG. Trained immunity as a novel therapeutic strategy. Curr Opin Pharmacol (2018) 41:52–8. 10.1016/j.coph.2018.04.007
- Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol (2018) 9:1–11. 10.3389/fimmu.2018.02936
- Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants–mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol (2008) 76:353–9.
- De Benedetto F, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidiscip Respir Med (2013) 8:1–9. 10.1186/2049-6958-8-33
- Collet JP, Shapiro S, Ernst P, Renzi P, Ducruet T, Robinson A, et al. . Effects of an Immunostimulating Agent on Acute Exacerbations and Hospitalizations in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (1997) 156:1719–24. 10.1164/ajrccm.156.6.9612096
- Alecsandru D, Valor L, Sánchez-Ramón S, Gil J, Carbone J, Navarro J, et al. . Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome: Sublingual immunization in patients with recurrent respiratory infections. Clin Exp Immunol (2011) 164:100–7. 10.1111/j.1365-2249.2011.04320.x
- Steurer-Stey C, Bachmann LM, Steurer J, Tramèr MR. Oral Purified Bacterial Extracts in Chronic Bronchitis and COPD. Chest (2004) 126:1645–55. 10.1378/chest.126.5.1645
- García González L-A, Arrutia Díez F. Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis. Hum Vaccines Immunother (2019) 15:2150–3. 10.1080/21645515.2019.1581537
- Conejero Hall L, Nieto García A, Brandi P, Nieto Cid M, Mazón Á, Cueto FJ, et al. . Bacterial immunotherapy in children with wheezing attacks: clinical impact and mechanism of action. Eur Respir J (2019) 54(Suppl.63):PA4998. 10.1183/13993003.congress-2019.PA4998
- Cirauqui C, Benito-Villalvilla C, Sánchez-Ramón S, Sirvent S, Diez-Rivero CM, Conejero L, et al. . Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways. Eur J Immunol (2018) 48:180–93. 10.1002/eji.201747024
- Molero-Abraham M, Sanchez-Trincado JL, Gomez-Perosanz M, Torres-Gomez A, Subiza JL, Lafuente EM, et al. . Human Oral Epithelial Cells Impair Bacteria-Mediated Maturation of Dendritic Cells and Render T Cells Unresponsive to Stimulation. Front Immunol (2019) 10:1–14. 10.3389/fimmu.2019.01434
- Sánchez Ramón S, Manzanares M, Candelas G. Vacunas antiinfecciosas de mucosas en la profilaxis de infecciones recurrentes: más allá de las vacunas convencionales. Reumatología Clínica (2020) 16:49–55. 10.1016/j.reuma.2018.10.012
- Guevara-Hoyer K, Saz-Leal P, Diez-Rivero CM, Ochoa-Grullón J, Fernández-Arquero M, Pérez de Diego R, et al. . Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study. Biomedicines (2020) 8:203. 10.3390/biomedicines8070203
- Tejera-Alhambra M, Palomares O, de Diego R, Diaz-Lezcano I, Sanchez-Ramon S. New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice. Curr Pharm Design (2016) 22:6283–93. 10.2174/1381612822666160829143129
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (2016) 127:2375–90. 10.1182/blood-2016-01-643569
- Tangcharoensathien V, Sattayawutthipong W, Kanjanapimai S, Kanpravidth W, Brown R, Sommanustweechai A. Antimicrobial resistance: from global agenda to national strategic plan, Thailand. Bull World Health Organ (2017) 95:599–603. 10.2471/BLT.16.179648
- Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen K-L, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol (2018) 18:198–209. 10.1097/ACI.0000000000000433
- Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJ. Cochrane Review: Immunostimulants for preventing respiratory tract infection in children. Evidence-Based Child Health: A Cochrane Rev J (2012) 7:629–717. 10.1002/ebch.1833
- Moreno-Fierros L, García-Silva I, Rosales-Mendoza S. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Expert Opin Biol Ther (2020) 20:831–6. 10.1080/14712598.2020.1767062
- Clancy RL, Dunkley M. Acute Exacerbations in COPD and Their Control with Oral Immunization with Non-Typeable Haemophilus Influenzae. Front Immunol (2011) 2:1–6. 10.3389/fimmu.2011.00007
- Pasquali C, Salami O, Taneja M, Gollwitzer ES, Trompette A, Pattaroni C, et al. . Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. Front Med (2014) 1:1–9. 10.3389/fmed.2014.00041
- Cheng S-C, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. . mTOR- and HIF-1 -mediated aerobic glycolysis as metabolic basis for trained immunity. Science (2014) 345:1250684–1250684. 10.1126/science.1250684
- Bulut O, Kilic G, Domínguez-Andrés J, Netea MG. Overcoming immune dysfunction in the elderly: trained immunity as a novel approach. Int Immunol (2020) 32(12):741–53. 10.1093/intimm/dxaa052
Source: PubMed